Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Receivables (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Receivables for 5 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 49.67% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2025, up 49.67%, and an annual FY2024 reading of $1.7 million, up 204.27% over the prior year.
  • Receivables was $1.6 million for Q3 2025 at X4 Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Across five years, Receivables topped out at $1.9 million in Q2 2025 and bottomed at $562000.0 in Q4 2023.
  • Average Receivables over 3 years is $1.3 million, with a median of $1.2 million recorded in 2025.
  • The sharpest move saw Receivables surged 204.27% in 2024, then skyrocketed 49.67% in 2025.
  • Year by year, Receivables stood at $562000.0 in 2023, then soared by 204.27% to $1.7 million in 2024, then decreased by 6.08% to $1.6 million in 2025.
  • Business Quant data shows Receivables for XFOR at $1.6 million in Q3 2025, $1.9 million in Q2 2025, and $1.2 million in Q1 2025.